Amakem banks €18M for ophthalmology drug studies

The Belgian biotech Amakem has raised €18 million ($25.2 million) in an impressive A round for its ophthalmology work. The biotech says it has enough money to get its lead candidate--a glaucoma drug called AMA0076--to clinical proof-of-concept. The round was led by Forbion Capital Partners and included Crédit Agricole Private Equity, Vesalius BioCapital, as well as the existing investors LRM, PMV and Life Sciences Research Partners. Release

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.